Paul Capital Partners established Paul Capital Healthcare in 1999 to meet the financing needs of healthcare companies, institutions and inventors. Today, the firm manages one of the largest dedicated healthcare funds globally with a total of $1.6 billion in assets under management. Paul Capital Healthcare has offices in New York, San Francisco, and London.

The Fund focuses on commercial stage healthcare products and investment opportunities in North America, Europe and Asia. To date Paul Capital Healthcare has closed more than 40 investments in the pharmaceutical, biotechnology, medical device and diagnostics areas. Public and private companies, research institutions and universities, and individual inventors have all benefited from the flexibility of Paul Capital Healthcare's investment approach. This capital has enabled them to transfer product risk, finance clinical and commercial development projects, acquire new products, fund university programs and capital needs, avoid conflicts of interest, unlock shareholder value and monetize product royalties.

Paul Capital Healthcare plays a passive or active role in its investments depending on the structure and size of the transaction. As active participants the Fund may take a seat on the board of directors or have board observer rights.